We have recently shown that in patients with HCV treated with paritaprevir/ritonavir/ombitasvir/dasabuvir (PrOD), with or without ribavirin, fasting glucose, insulin, and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) are unchanged during treatment and follow-up after treatment (58). This evidence concerns the gene INS and Insulin resistance.